Effects of recombinant human insulin-like growth factor I administration on the growth hormone (GH) response to GH-releasing hormone in obesity

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 1, 2001, Pages 167-171

  Maccario, M ^a   Tassone, F ^a   Gianotti, L ^a   Lanfranco, F ^a   Grottoli, S ^a   Arvat, E ^a   Muller, E E ^a   Ghigo, E ^a  

^a MOLINETTE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; GLUCOSE; GROWTH HORMONE RELEASING FACTOR; INSULIN; PIRENZEPINE; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN C;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; FEMALE; FLUSHING; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HORMONE RESPONSE; HORMONE SENSITIVITY; HUMAN; NEGATIVE FEEDBACK; OBESITY; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; SKIN INJURY;

ABDOMEN; ADULT; BLOOD GLUCOSE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GROWTH HORMONE-RELEASING HORMONE; HUMAN GROWTH HORMONE; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; OBESITY; RECOMBINANT PROTEINS; THINNESS;

EID: 0035142215     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.86.1.167     Document Type: Article

References (58)

1. Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man
2. Impaired growth hormone secretion in spontaneous experimental obesity: A result of increased somatostatin (SRIF) tone
3. Mechanism of impaired growth hormone secretion in genetically obese Zucker rats: Roles of growth hormone-releasing factor and somatostatin
4. Repetitive GHRH administration fails to increase to GHRH in obese subjects. Evidence for a somatotrope defect in obesity?
5. Free insulin-like growth factor in human obesity
6. Effect of insulin on the hepatic production of insulin-like growth factor binding protein-1 (IGFBP-1), IGFBP-3 and IGF-I in insulin-dependent diabetics
7. Metabolic Modulation of growth hormone-releasing activity of hexarelin in man
8. Effects of acipimox, an antilipolytic drug, on the growth hormone (GH). Response to GH-releasing hormone alone or combined with arginine in obesity
9. Neuroendocrine regulation and actions of leptin
10. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression
11. Long-term administration of acipimox potentiates growth hormone response to growth hormone-releasing hormone by decreasing serum free fatty acid in obesity
12. Evidence for a direct pituitary inhibition by free fatty acid of in vivo growth hormone responses to growth hormone-releasing hormone in the rat
13. Acute pharmacological blockade of lypolisis normalizes nocturnal growth hormone levels and pulsatily in obese subjects
14. Effect of insulin on rat anterior pituitary cells
15. Suppression of counterregulatory hormone response to hypoglycemia by insulin per se
16. Effect of arginine on serum levels of insulin and growth hormone in obese subjects
17. Pituitary response to insulin-induced hypoglycemia in obese subjects before and after fasting
18. The effect of a single dose of L-dopa on pituitary hormones in acromegaly, obesity and in normal subjects
19. Plasma growth hormone response to oral clonidine as compared to insulin hypoglycemia in obese children and adolescents
20. The effects of enkephalin analogue on pituitary hormone release in human obesity
21. Effect of cholinergic enhancement by pyridostigrnine on growth hormone secretion obese adults and children
22. The effect of galanin on baseline and GHRH-induced growth hormone secretion in obese children
23. Role of glucocorticoids in the neuroregulation of growth hormone secretion
24. Impaired growth hormone releasing factor in obesity
25. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects
26. GH responsiveness to combined administration of arginine and GHRH does not vary with age in man
27. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: Evidence for a marked somatotroph secretory capability in obesity
28. GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: Obesity and Cushing's syndrome in comparison with hypopituitarism
29. In obesity, glucose load loses its early inhibitory, but maintains its late stimulatory, effect on somatotrope secretion
30. In obesity the somatotrope response to either growth hormone-releasing hormone or arginine is inhibited by somatostatin or pirenzepine but not by glucose
31. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans
32. Effect of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects
33. IGF-I attenuates the GH response to arginine
34. Biochemical and hormonal changes induced by one week of administration of rhIGF-I to patients with Laron type dwarfism
35. A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans
36. Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome
37. The relationship between overnight GH levels and insulin concentrations in adolescents with insulin-dependent diabetes mellitus (IDDM) and the impact of recombinant human insulin-like growth factor-I (rhIGF-I)
38. The growth hormone (GH)-releasing hormone (GHRH)-GH-somatomedin axis: Evidence for rapid inhibition of GHRH-elicited GH release by insulin-like growth factors I and II
39. Somatomedin-C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary
40. Human growth hormone and somatomedin C suppress the spontaneous release of growth hormone in unanesthetized rats
41. Insulin-like growth factors: A role in growth hormone negative feedback and body weight regulation via brain
42. Insulin-like growth factor I action on rat anterior pituitary cells: Suppression of growth hormone secretion and messenger ribonucleic acid levels
43. IGF feedback effects on growth hormone secretion in ewes: Evidence for action at the pituitary but not the hypothalamic level
44. Identification of binding sites for an insulin-like growth factor (IGF-I) in the median eminence of the rat brain by quantitative autoradiography
45. Human fetal pituitary expresses functional growth hormone-releasing peptide receptors
46. Differential effects of central and peripheral administration of GH and insulin-like growth factor on hypothalamic GH-releasing hormone and somatostatin gene expression in GH-deficient dwarf rats
47. In vitro release of growth hormone-releasing factor from rat hypothalamus: Effect of insulin-like growth factor-I
48. Effects of recombinant human insulin-like growth factor I administration on spontaneous and growth hormone (GH)-releasing hormone-stimulated GH secretion in anorexia nervosa
49. The effect of recombinant IGF-I on anterior pituitary function in healthy volunteers
50. Growth hormone-releasing hormone
51. Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans
52. Intravenous administration of recombinant IGF-I lowers serum GHRH and TSH
53. Neurotransmitter regulation of the anterior pituitary
54. New modalities for understanding dynamic regulation of the somatotropic (GH) axis: Explication of gender differences in GH neuroregulation in the human
55. Hormone pulsatility discrimination via coarse and short time sampling
56. Insulin-like growth factor-I in man enhances lipid mobilization and oxidation induced by a growth hormone pulse
57. Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humans